Evidence map›Paper›PMID 31234897›Full record

ReviewParasites & vectors2019

Erythrocyte glycophorins as receptors for Plasmodium merozoites.

Ewa Jaskiewicz, Marlena Jodłowska, Radosław Kaczmarek, Agata Zerka

Open access · goldAbstract readReview
In one paragraph

Review in Parasites & vectors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Human genetic variations conferring resistance to malaria.Journal of translational medicine · 2025
    Review
  8. Ficolin-1 in pediatricInfection and immunity · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Host-pathogen interactions involved in erythrocyte invasion byFrontiers in cellular and infection microbiology · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Local genetic adaptation to habitat in wild chimpanzees.bioRxiv : the preprint server for biology · 2024
    Article
  18. Article
  19. Cells · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ewa JaskiewiczLaboratory of Glikobiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114, Wroclaw, Poland. ewa.jaskiewicz@hirszfeld.pl.
Marlena JodłowskaLaboratory of Glikobiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114, Wroclaw, Poland.
Radosław KaczmarekLaboratory of Glikobiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114, Wroclaw, Poland.
Agata ZerkaLaboratory of Glikobiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114, Wroclaw, Poland.
Polish Academy of Sciences · PLLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PL

Funding

National Centre of Science, Poland Harmonia UMO-2018/30/M/NZ6/00653National Centre of Science, Poland. Preludium UMO-2016/23/N/NZ6/01462
6 · The paper itself

Abstract

Glycophorins are heavily glycosylated sialoglycoproteins of human and animal erythrocytes. In humans, there are four glycophorins: A, B, C and D. Glycophorins play an important role in the invasion of red blood cells (RBCs) by malaria parasites, which involves several ligands binding to RBC receptors. Four Plasmodium falciparum merozoite EBL ligands have been identified: erythrocyte-binding antigen-175 (EBA-175), erythrocyte-binding antigen-181 (EBA-181), erythrocyte-binding ligand-1 (EBL-1) and erythrocyte-binding antigen-140 (EBA-140). It is generally accepted that glycophorin A (GPA) is the receptor for P. falciparum EBA-175 ligand. It has been shown that α(2,3) sialic acid residues of GPA O-glycans form conformation-dependent clusters on GPA polypeptide chain which facilitate binding. P. falciparum can also invade erythrocytes using glycophorin B (GPB), which is structurally similar to GPA. It has been shown that P. falciparum EBL-1 ligand binds to GPB. Interestingly, a hybrid GPB-GPA molecule called Dantu is associated with a reduced risk of severe malaria and ameliorates malaria-related morbidity. Glycophorin C (GPC) is a receptor for P. falciparum EBA-140 ligand. Likewise, successful binding of EBA-140 depends on sialic acid residues of N- and O-linked oligosaccharides of GPC, which form a cluster or a conformational structure depending on the presence of peptide fragment encompassing amino acids (aa) 36-63. Evaluation of the homologous P. reichenowi EBA-140 unexpectedly revealed that the chimpanzee homolog of human glycophorin D (GPD) is probably the receptor for this ligand. In this review, we concentrate on the role of glycophorins as erythrocyte receptors for Plasmodium parasites. The presented data support the long-lasting idea of high evolutionary pressure exerted by Plasmodium on the human glycophorins, which emerge as important receptors for these parasites.

Indexed as

AnimalsCarrier ProteinsErythrocytesGlycophorinsHumansLigandsMembrane ProteinsMerozoitesPan troglodytesPlasmodium falciparumProtein BindingProtozoan ProteinsReceptors, Cell SurfaceCarrier ProteinsEBA140 protein, Plasmodium falciparumGlycophorinsLigandsMembrane ProteinsProtozoan ProteinsReceptors, Cell SurfaceErythrocyte glycophorins A, B, C, DMalaria resistancePlasmodium EBA merozoite ligandsReceptor-ligand interaction

Identifiers

PMID31234897
PMCPMC6591965
OpenAlexW2949697884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.